The firm said revenues fell because of delayed shipments of HIV self-tests and ongoing softness in the consumer genomics markets.
The tests run on the firm's sample-to-result automated molecular diagnostics instruments designed for use by high-volume labs.
The firm reported declines in revenues from its molecular collections systems, genomics products, and infectious disease tests, but still beat analyst estimates.
The firm said its new molecular platform, which offers random-access testing, high throughput, and a broad menu has the potential to replace multiple instruments in molecular labs.
The kit, which was launched today, leverages real-time RT-PCR technology to detect and quantify hepatitis C virus-specific RNA with genotypes 1 to 6.
The firm said net product revenues fell 11 percent year over year in the fourth quarter.
The assay is designed to quantitate HBV DNA in serum or plasma to assist in the treatment of chronic HBV-infected patients receiving antiviral therapy.
Developers of POC STI platforms and assays said that the tests provide convenience, privacy, and quick results in an area of testing in need of these benefits.
Qorvo Biotechnologies and Novel Biomarkers Catalyst Lab are developing prototype cartridge-based HCV cAg assays for confirmatory testing.
The company said its molecular collection systems products saw the highest revenue growth during the quarter as product revenues rose 6 percent overall.